The mammalian target of rapamycin (mTOR) is a central regulator of cell proliferation that is
often deregulated in cancer. Inhibitors of mTOR, including rapamycin and its analogues, are
being evaluated as antitumor agents. For their promise to be fulfilled, it is of paramount
importance to identify the mechanisms of resistance and develop novel therapies to
overcome it. Given the emerging role of microRNAs (miRNAs) in tumorigenesis, we
hypothesized that miRNAs could play important roles in the response of tumors to mTOR …